Funding
← Back to your selection

Cormorant Asset Management

Activity from announced rounds

Activity in this selectionxyz-venture-capital-d246227f
Rounds participated in
4
Confirmed lead rounds
—
4 roles undisclosed
New companies
4
First participation on record · 0 follow-on
Funding in participating rounds
$633M
4 disclosed · full round size, not this investor’s share

By stage

Series C+3
Series B1

By primary sector

Biotech4

By country

United States4

Rounds

4 in this selection
Crystalys Therapeutics

Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout

$130MSeries B
Role not disclosed
Terremoto Biosciences

Develops highly targeted, small molecule medicines for cancer and rare diseases

$108MSeries C
Role not disclosed
Parabilis Medicines

Develops medicines targeting historically undruggable protein targets in cancer

$305MSeries F
Role not disclosed